Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448926 · ClinicalTrials.gov registry record
The PREDICT Registry:
A clinical trial of DCIS, sponsored by PreludeDx.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 15
- Study locations
NCT03448926: Recruiting study of DCIS, sponsored by PreludeDx.
NCT03448926 is a study of DCIS that is actively recruiting participants, run by PreludeDx. The registered enrollment target is 3,000 participants, above the 236-participant average among 9 other DCIS trials with a reported enrollment target (1171% higher). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03448926, a study of DCIS, is actively recruiting participants, sponsored by PreludeDx.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.
Primary Outcome
The percent of cases in which treatment recommendations are changed after the test DCISionRT test results become available. The study will collect details on physician treatment recommendations and patient preference before and after the availability of the molecular test (DCISionRT) results. The data elements include type of surgery (lumpectomy, therapeutic mastectomy, contralateral prophylactic mastectomy), type of radiation therapy (none, IORT, APBI/PBI, whole breast RT, boost) and endocrine
Conditions Studied
Interventions
- OTHER Treatment Recommendation Surveys
- DEVICE 7-gene biosignature
Study Locations (15)
Ohio
- Cleveland Clinic Akron General - Akron
- Cleveland Clinic Foundation Taussig Cancer Institute - Cleveland
- The Ohio State University - Columbus
California
- Sutter Institute for Medical Research - Sacramento
- Mills-Peninsula Medical Center - San Mateo
Colorado
- University of Colorado Denver - Aurora
- UC Health - Memorial Hospital, Colorado Springs - Colorado Springs
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Dana-Farber/Brigham and Women's Cancer Center at South Shore - South Weymouth
Arizona
- Arizona Center for Cancer Care - Phoenix
Florida
- St. Joseph's Hospital Tampa - Tampa
Michigan
- Comprehensive Breast Care - Troy
New York
- Maimonides Cancer Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2035-12 |
What NCT03448926 shows while recruiting
NCT03448926 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 236-participant average among 9 other DCIS trials with a reported enrollment target (1171% higher).
The record links to 1 condition, with DCIS appearing as the primary indexed condition, and to 2 interventions - of which Treatment Recommendation Surveys is the first listed.
NCT03448926 lists 15 locations in 10 states (Ohio, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT03448926 about?
NCT03448926 is a clinical study titled "The PREDICT Registry:". This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed...
What is the current status of trial NCT03448926?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2018-02-27. Estimated completion is 2035-12.
What conditions does trial NCT03448926 study?
This clinical trial studies the following conditions: DCIS.
What interventions are being tested in trial NCT03448926?
The interventions under investigation include: Treatment Recommendation Surveys (OTHER), 7-gene biosignature (DEVICE).
Who is sponsoring clinical trial NCT03448926?
This trial is sponsored by PreludeDx, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03448926 being conducted?
This trial has 15 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for DCIS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03448926's enrollment target sits among peer trials
3,000 1st of 9 higher than 9 of 9 other DCIS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other DCIS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
RECRUITING · Phase 2
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
Perioperative Mindfulness Proposal
RECRUITING · NA
-
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
RECRUITING · Phase 2
-
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI